Literature DB >> 23791857

Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations.

J J Ott1, S T Wiersma.   

Abstract

OBJECTIVES: Our objective was to identify evidence on the protection achieved by single-dose use of inactivated hepatitis A vaccines in order to evaluate the potential of a flexible booster administration in the form of a second dose.
METHODS: A search was conducted for evidence on single-dose administration of inactivated hepatitis A vaccine and its potential impacts on long-term seropositivity rates. The main pharmaceutical vaccine manufacturer federations and the corresponding authors of manuscripts were approached for additional epidemiologic data. Correspondence was also sent to the Argentinean Ministry of Health.
RESULTS: We identified 15 data sources reporting on protection achieved by a single dose of inactivated hepatitis A vaccine. The consistent finding was that the immune and memory response to the booster dose, or post-booster geometric mean titer, was independent of the time since initial vaccination. The impact of the booster on seroprotection was the same across sexes and age-groups. The longest time interval between initial and booster dose was 10.67 years, indicating that booster doses can be highly immunogenic for up to 10.67 years after primary vaccination.
CONCLUSIONS: Protective anti-hepatitis A virus antibody levels after a single dose of inactivated hepatitis A vaccine can persist for almost 11 years and increase or reappear after booster vaccination. Further research on the vaccine doses needed to achieve long-term protection against hepatitis A infection is required.
Copyright © 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Booster; Dosage; Hepatitis A virus; Inactivated vaccine

Mesh:

Substances:

Year:  2013        PMID: 23791857     DOI: 10.1016/j.ijid.2013.04.012

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  20 in total

1.  Reply to Nalin.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2015-08-12       Impact factor: 5.226

2.  Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine.

Authors:  Zhilun Zhang; Xiangjun Zhu; Yuansheng Hu; Miao Liang; Jin Sun; Yufei Song; Qi Yang; Haiquan Ji; Gang Zeng; Lifei Song; Jiangting Chen
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

3.  Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose.

Authors:  Xiaoshu Zhang; Jing An; Aixia Tu; Xuefeng Liang; Fuqiang Cui; Hui Zheng; Yu Tang; Jianfeng Liu; Xuxia Wang; Ningjing Zhang; Hui Li
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

4.  Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.

Authors:  Vladimir Gilca; Chantal Sauvageau; Gitika Panicker; Gaston De Serres; John Schiller; Manale Ouakki; Elisabeth R Unger
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

5.  Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children.

Authors:  Abigail Hankin-Wei; David B Rein; Alfonso Hernandez-Romieu; Mallory J Kennedy; Lisa Bulkow; Eli Rosenberg; Monica Trigg; Noele P Nelson
Journal:  Vaccine       Date:  2016-06-27       Impact factor: 3.641

6.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

7.  Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children.

Authors:  Monjori Mitra; Nitin Shah; Mma Faridi; Apurba Ghosh; V S Sankaranarayanan; Anju Aggarwal; Suparna Chatterjee; Nisha Bhattacharyya; Ganesh Kadhe; Gaurav Vishnoi; Amey Mane
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.

Authors:  Yeong-Jun Song; Jiseun Lim; Woong-Sub Park; Haesook Sohn; Moo-Sik Lee; Dong-Hoon Shin; Chun-Bae Kim; Hwasung Kim; Gyung-Jae Oh; Moran Ki
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

9.  Decreasing risk of hepatitis A infection in León, Nicaragua: evidence from cross-sectional and longitudinal seroepidemiology studies.

Authors:  Orlando Mayorga Perez; Martin W G Brinkhof; Matthias Egger; Gert Frösner; Christian Herzog; Marcel Zwahlen
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

10.  Pattern of Hepatitis A Virus Epidemiology in Nursing Students and Adherence to Preventive Measures at Two Training Wards of a University Hospital.

Authors:  Marcello Campagna; Noemi Maria Mereu; Lucia Mulas; Roberta Pilia; Maria Francesca Piazza; Laura Spada; Alberto Lai; Igor Portoghese; Maura Galletta; Giuseppina Masia; Angelo Restivo; Paolo Mura; Gabriele Finco; Rosa Cristina Coppola
Journal:  Hepat Mon       Date:  2016-02-27       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.